Evidence map›Paper›PMID 38158612›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2023

4-Octyl itaconate alleviates renal ischemia reperfusion injury by ameliorating endoplasmic reticulum stress via Nrf2 pathway.

Xiang-Kun Li, Hong-Juan Yang, Shi-Han Du, Bing Zhang, Ling-Yu Li, Shao-Na Li, Cui-Cui Liu, Yang Ma, Jian-Bo Yu

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Itaconate metabolism in regulated cell death.Molecular and cellular biochemistry · 2026
    Review
  2. Itaconate and its derivatives in human health and diseases.Signal transduction and targeted therapy · 2026
    Review
  3. Intercellular transfer of LncRNABiochemistry and biophysics reports · 2026
    Article
  4. Review
  5. Reprogramming immunity with itaconate: metabolic mechanisms and therapeutic perspectives.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiang-Kun LiDepartment of Anesthesiology and Critical Care Medicine, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China.
Hong-Juan YangDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Shi-Han DuDepartment of Anesthesiology and Critical Care Medicine, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China.
Bing ZhangDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Ling-Yu LiDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Shao-Na LiDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Cui-Cui LiuDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Yang MaDepartment of Anesthesiology and Critical Care Medicine, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China.
Jian-Bo YuDepartment of Anesthesiology and Critical Care Medicine, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin 300100, China.ORCID 0000-0003-0530-6749
Qingdao University · CNTianjin Nankai Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal ischemia-reperfusion injury (IRI) is a common clinical complication of multiple severe diseases. Owing to its high mortality and the lack of effective treatment, renal IRI is still an intractable problem for clinicians. Itaconate, which is a metabolite of cis-aconitate, can exert anti-inflammatory and antioxidant roles in many diseases. As a derivative of itaconate with high cell membrane permeability, 4-octyl itaconate (4-OI) could provide a protective effect for various diseases. However, the role of 4-OI in renal IRI is still unclear. Herein, we examined whether 4-OI afforded kidney protection through attenuating endoplasmic reticulum stress (ERS) via nuclear factor erythroid-2-related factor 2 (Nrf2) pathway. To observe the effects of 4-OI on alleviating renal pathologic injury, improving renal dysfunction, decreasing inflammatory cytokines, and reducing oxidative stress, we utilized C57BL/6J mice with bilateral renal pedicle clamped and HK-2 cells with hypoxia/reoxygenation (H/R) exposure in our study. In addition, through western blot assay, we found 4-OI ameliorated renal IRI-induced ERS, and activated Nrf2 pathway. Moreover, Nrf2-knockout (KO) mice and Nrf2 knockdown HK-2 cells were used to validate the role of Nrf2 signaling pathway in 4-OI-mediated alleviation of ERS caused by renal IRI. We demonstrated that 4-OI relieved renal injury and suppressed ERS in wild-type mice, while the therapeutic role was not shown in Nrf2-KO mice. Similarly, 4-OI could exert cytoprotective effect and inhibit ERS in HK-2 cells after H/R, but not in Nrf2 knockdown cells. Our

Indexed as

NF-E2-Related Factor 2Reperfusion InjurySuccinatesAnimalsApoptosisEndoplasmic Reticulum StressKidneyMiceMice, Inbred C57BLOxidative Stress4-octyl itaconateitaconic acidNF-E2-Related Factor 2Succinates4-Octyl itaconate (4-OI)endoplasmic reticulum stress (ERS)ischemia-reperfusion injury (IRI)nuclear factor erythroid-2-related factor 2 (Nrf2)

Identifiers

PMID38158612
PMCPMC10903237
OpenAlexW4390449330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.